You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: ENDECTRA, LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Cryopreservation and Cloning of Somatic Cells to Preserve Zebrafish Germplasm

    SBC: FreezeBack, LLC            Topic: OD

    DESCRIPTION provided by applicant Freezing whole zebrafish embryos in order to later recover live fish is not currently possible Researchers seeking to preserve zebrafish genetic lines are presently limited to the options of storing frozen sperm in sperm banks or maintaining the fish alive These limitations increase costs and hinder the efficient dissemination of superior wild type and mutan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)

    SBC: Tymora Analytical Operations, LLC            Topic: NIA

    PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Developing high throughput measurement of thiopurine in DNA by mass spectrometry

    SBC: Tymora Analytical Operations, LLC            Topic: 400

    PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Developing novel RPPA for the detection of metastatic prostate cancer

    SBC: Tymora Analytical Operations, LLC            Topic: 102

    PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents

    SBC: Grannus Therapeutics, Inc.            Topic: NCI

    Abstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government